Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Receivables: 2020-2025

Historic Change in Receivables for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to $2.4 million.

  • Journey Medical's Change in Receivables rose 175.37% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 98.23%. This contributed to the annual value of -$4.5 million for FY2024, which is 64.35% up from last year.
  • Per Journey Medical's latest filing, its Change in Receivables stood at $2.4 million for Q3 2025, which was up 185.58% from -$2.8 million recorded in Q2 2025.
  • Journey Medical's 5-year Change in Receivables high stood at $8.0 million for Q1 2022, and its period low was -$10.4 million during Q2 2023.
  • Its 3-year average for Change in Receivables is -$858,545, with a median of -$466,000 in 2023.
  • The largest annual percentage gain for Journey Medical's Change in Receivables in the last 5 years was 14,170.59% (2023), contrasted with its biggest fall of 10,538.55% (2023).
  • Quarterly analysis of 5 years shows Journey Medical's Change in Receivables stood at -$8.5 million in 2021, then skyrocketed by 99.40% to -$51,000 in 2022, then surged by 14,170.59% to $7.2 million in 2023, then tumbled by 110.41% to -$747,000 in 2024, then surged by 175.37% to $2.4 million in 2025.
  • Its Change in Receivables stands at $2.4 million for Q3 2025, versus -$2.8 million for Q2 2025 and $8.0 million for Q1 2025.